Unaltered Oxytocin and Vasopressin Plasma Levels in Patients with Schizophrenia After 4 Months of Daily Treatment with Intranasal Oxytocin

Journal of Neuroendocrinology

Volumn 28, Issue 4, 2016, Pages

  Busnelli, M ^a,b   Dagani, J ^c   de Girolamo, G ^c   Balestrieri, M ^d   Pini, S ^e   Saviotti, F M ^f   Scocco, P ^g   Sisti, D ^h   Rocchi, M ^h   Chini, B ^a,i  

^a CNR   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f Department of Mental Health ^*  (Italy)

^g Azienda ULSS 16 Padova   (Italy)

^h UNIVERSITY OF URBINO   (Italy)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Chronic treatment; Intranasal oxytocin; Oxytocin dosage; Radioimmunoassay; Schizophrenia

Indexed keywords

OXYTOCIN; PLACEBO; SODIUM; VASOPRESSIN; AVP PROTEIN, HUMAN; NEUROPHYSIN; PROTEIN PRECURSOR; VASOPRESSIN DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; OBESITY; PLASMA OSMOLALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASOPRESSIN BLOOD LEVEL; ADOLESCENT; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; EATING; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; OSMOLARITY; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EATING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPHYSINS; OSMOLAR CONCENTRATION; OXYTOCIN; PROTEIN PRECURSORS; SCHIZOPHRENIA; SODIUM; VASOPRESSINS; YOUNG ADULT;

EID: 84964994643     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/jne.12359     Document Type: Article

References (46)

1. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 2010; 77: 317-326.
2. Matosin N, Frank E, Deng C, Huang XF, Newell KA. Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophr Res 2013; 146: 170-176.
3. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 2004; 27: 683-690.
4. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008; 33: 2061-2079.
5. Cochran DM, Fallon D, Hill M, Frazier JA. The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings. Harv Rev Psychiatry 2013; 21: 219-247.
6. Cacciotti-Saija C, Langdon R, Ward PB, Hickie IB, Scott EM, Naismith SL, Moore L, Alvares GA, Redoblado Hodge MA, Guastella AJ. A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophr Bull 2015; 41: 483-493.
7. Feifel D, Shilling PD, MacDonald K. A review of oxytocin's effects on the positive, negative, and cognitive domains of schizophrenia. Biol Psychiatry 2016; 79: 222-233.
8. Leng G, Ludwig M. Intranasal oxytocin: myths and delusions. Biol Psychiatry 2015; 79: 243-250.
9. Neumann ID, Maloumby R, Beiderbeck DI, Lukas M, Landgraf R. Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology 2013; 38: 1985-1993.
10. Chang SW, Barter JW, Ebitz RB, Watson KK, Platt ML. Inhaled oxytocin amplifies both vicarious reinforcement and self reinforcement in rhesus macaques (Macaca mulatta). Proc Natl Acad Sci USA 2012; 109: 959-964.
11. Dal Monte O, Noble PL, Turchi J, Cummins A, Averbeck BB. CSF and blood oxytocin concentration changes following intranasal delivery in macaque. PLoS ONE 2014; 9: e103677.
12. Modi ME, Connor-Stroud F, Landgraf R, Young LJ, Parr LA. Aerosolized oxytocin increases cerebrospinal fluid oxytocin in rhesus macaques. Psychoneuroendocrinology 2014; 45: 49-57.
13. Striepens N, Kendrick KM, Hanking V, Landgraf R, Wullner U, Maier W, Hurlemann R. Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep 2013; 3: 3440.
14. Bethlehem RA, van Honk J, Auyeung B, Baron-Cohen S. Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies. Psychoneuroendocrinology 2013; 38: 962-974.
15. De Groot AN, Vree TB, Hekster YA, Pesman GJ, Sweep FC, Van Dongen PJ, Van Roosmalen J. Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. J Pharm Pharmacol 1995; 47: 571-575.
16. Mens WB, Laczi F, Tonnaer JA, de Kloet ER, van Wimersma Greidanus TB. Vasopressin and oxytocin content in cerebrospinal fluid and in various brain areas after administration of histamine and pentylenetetrazol. Pharmacol Biochem Behav 1983; 19: 587-591.
17. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001; 81: 629-683.
18. MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011; 36: 1114-1126.
19. Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry 2015; doi: 10.1038/mp.2015.162.
20. Martin J, Kagerbauer SM, Schuster T, Blobner M, Kochs EF, Landgraf R. Vasopressin and oxytocin in CSF and plasma of patients with aneurysmal subarachnoid haemorrhage. Neuropeptides 2014; 48: 91-96.
21. Landgraf R. Simultaneous measurement of arginine vasopressin and oxytocin in plasma and neurohypophyses by radioimmunoassay. Endokrinologie 1981; 78: 191-204.
22. Worthley LI, Guerin M, Pain RW. For calculating osmolality, the simplest formula is the best. Anaesth Intensive Care 1987; 15: 199-202.
23. Martin-Calderon JL, Bustos F, Tuesta-Reina LR, Varona JM, Caballero L, Solano F. Choice of the best equation for plasma osmolality calculation: comparison of fourteen formulae. Clin Biochem 2015; 48: 529-533.
24. Grizzle J. The two-period change-over design and its use in clinical trials. Biometrics 1965; 22: 469-480.
25. Christensen JC, Shiyanov PA, Estepp JR, Schlager JJ. Lack of association between human plasma oxytocin and interpersonal trust in a Prisoner's Dilemma paradigm. PLoS One 2014; 9: e116172.
26. El-Farhan N, Hampton D, Penney M. Measurement of arginine vasopressin. Methods Mol Biol 2013; 1065: 129-139.
27. Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am 2001; 30: 671-694, vii.
28. Catapano L, Castle D. Obesity in schizophrenia: what can be done about it? Australas Psychiatry 2004; 12: 23-25.
29. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry 2001; 46: 549-555.
30. McCullough ME, Churchland PS, Mendez AJ. Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? Neurosci Biobehav Rev 2013; 37: 1485-1492.
31. Zhang G, Zhang Y, Fast DM, Lin Z, Steenwyk R. Ultra sensitive quantitation of endogenous oxytocin in rat and human plasma using a two-dimensional liquid chromatography-tandem mass spectrometry assay. Anal Biochem 2011; 416: 45-52.
32. Petersson M. Cardiovascular effects of oxytocin. Prog Brain Res 2002; 139: 281-288.
33. Wsol A, Szczepanska-Sadowska E, Kowalewski S, Puchalska L, Cudnoch-Jedrzejewska A. Oxytocin differently regulates pressor responses to stress in WKY and SHR rats: the role of central oxytocin and V1a receptors. Stress 2014; 17: 117-125.
34. Sartain JB, Barry JJ, Howat PW, McCormack DI, Bryant M. Intravenous oxytocin bolus of 2 units is superior to 5 units during elective Caesarean section. Br J Anaesth 2008; 101: 822-826.
35. Simpson KR, Knox GE. Oxytocin as a high-alert medication: implications for perinatal patient safety. MCN Am J Matern Child Nurs 2009; 34: 8-15.
36. Thomas JS, Koh SH, Cooper GM. Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing Caesarean section. Br J Anaesth 2007; 98: 116-119.
37. Kirkpatrick MG, Francis SM, Lee R, de Wit H, Jacob S. Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans. Psychoneuroendocrinology 2014; 46: 23-31.
38. Phie J, Haleagrahara N, Newton P, Constantinoiu C, Sarnyai Z, Chilton L, Kinobe R. Prolonged subcutaneous administration of oxytocin accelerates angiotensin II-induced hypertension and renal damage in male rats. PLoS ONE 2015; 10: e0138048.
39. Blackburn RE, Samson WK, Fulton RJ, Stricker EM, Verbalis JG. Central oxytocin inhibition of salt appetite in rats: evidence for differential sensing of plasma sodium and osmolality. Proc Natl Acad Sci USA 1993; 90: 10380-10384.
40. Ansseau M, Legros JJ, Mormont C, Cerfontaine JL, Papart P, Geenen V, Adam F, Franck G. Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology 1987; 12: 231-236.
41. Seifer DB, Sandberg EC, Ueland K, Sladen RN. Water intoxication and hyponatremic encephalopathy from the use of an oxytocin nasal spray. A case report. J Reprod Med 1985; 30: 225-228.
42. Mayer-Hubner B. Pseudotumour cerebri from intranasal oxytocin and excessive fluid intake. Lancet 1996; 347: 623.
43. Ott V, Finlayson G, Lehnert H, Heitmann B, Heinrichs M, Born J, Hallschmid M. Oxytocin reduces reward-driven food intake in humans. Diabetes 2013; 62: 3418-3425.
44. Olson BR, Drutarosky MD, Stricker EM, Verbalis JG. Brain oxytocin receptor antagonism blunts the effects of anorexigenic treatments in rats: evidence for central oxytocin inhibition of food intake. Endocrinology 1991; 129: 785-791.
45. Sabatier N, Leng G, Menzies J. Oxytocin, feeding, and satiety. Front Endocrinol (Lausanne) 2013; 4: 35.
46. Iwasaki Y, Maejima Y, Suyama S, Yoshida M, Arai T, Katsurada K, Kumari P, Nakabayashi H, Kakei M, Yada T. Peripheral oxytocin activates vagal afferent neurons to suppress feeding in normal and leptin-resistant mice: a route for ameliorating hyperphagia and obesity. Am J Physiol Regul Integr Comp Physiol 2015; 308: R360-R369.